All Title Author
Keywords Abstract

PLOS ONE  2013 

Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis

DOI: 10.1371/journal.pone.0079669

Full-Text   Cite this paper   Add to My Lib


Background Respiratory isolation of inpatients during evaluation for TB is a slow and costly process in low-burden settings. Xpert MTB/RIF (Xpert) is a novel molecular test for tuberculosis (TB) that is faster and more sensitive but substantially more expensive than smear microscopy. No previous studies have examined the costs of molecular testing as a replacement for smear microscopy in this setting. Methods We conducted an incremental cost–benefit analysis comparing the use of a single negative Xpert versus two negative sputum smears to release consecutive adult inpatients with presumed TB from respiratory isolation at an urban public hospital in the United States. We estimated all health-system costs and patient outcomes related to Xpert implementation, diagnostic evaluation, isolation, hospitalization, and treatment. We performed sensitivity and probabilistic uncertainty analyses to determine at what threshold the Xpert strategy would become cost-saving. Results Among a hypothetical cohort of 234 individuals undergoing evaluation for presumed active TB annually, 6.4% had culture-positive TB. Compared to smear microscopy, Xpert reduced isolation bed utilization from an average of 2.7 to 1.4 days per patient, leading to a 48% reduction in total annual isolation bed usage from 632 to 328 bed-days. Xpert saved an average of $2,278 (95% uncertainty range $1582–4570) per admission, or $533,520 per year, compared with smear microscopy. Conclusions Molecular testing for TB could provide substantial savings to hospitals in high-income countries by reducing respiratory isolation usage and overall length of stay.


[1]  Lawn SD, Zumla AI (2011) Tuberculosis. Lancet 378: 57–72.
[2]  Jensen P, Lambert L, Iademarco M, Ridzon R (2005) Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 54: 1–141.
[3]  Pavelchak N, DePersis RP, London M, Stricof R, Oxtoby M, et al. (2000) Identification of factors that disrupt negative air pressurization of respiratory isolation rooms. Infect Control Hosp Epidemiol 21: 191–195.
[4]  Wilmer A, Bryce E, Grant J (2011) The role of the third acid-fast bacillus smear in tuberculosis screening for infection control purposes: A controversial topic revisited. Can J Infect Dis Med Microbiol 22: E1–E3.
[5]  Moore D, Guzman J, Mikhail L (2005) Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test. Diagn Microbiol Infect Dis: 247–252.
[6]  Tokars JI, McKinley GF, Otten J, Woodley C, Sordillo EM, et al. (2001) Use and efficacy of tuberculosis infection control practices at hospitals with previous outbreaks of multidrug-resistant tuberculosis. Infect Control Hosp Epidemiol 22: 449–455.
[7]  Wisnivesky J, Henschke C, Balentine J, Willner C, Deloire A, et al. (2005) Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis. Arch Intern Med 165: 453–457.
[8]  Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, et al. (2000) The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: Results of a multicenter prospective trial. JAMA 283: 639–645.
[9]  Greco S, Girardi E, Navarra A, Saltini C (2006) Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 61: 783–790.
[10]  Campos M, Quartin A, Mendes E, Abreu A, Gurevich S, et al. (2008) Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification test. Am J Respir Crit Care Med 178: 300–305.
[11]  Laraque F, Griggs A, Slopen M, Munsiff S (2009) Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin Infect Dis 49: 46–54.
[12]  Drobniewski FA, Watt B, Smith EG, Magee JG, Williams R, et al. (1999) A national audit of the laboratory diagnosis of tuberculosis and other mycobacterial diseases within the United Kingdom. J Clin Pathol 52: 334–337.
[13]  Dowdy DW, Maters A, Parrish N, Breyer C, Dorman S (2003) Cost-effectiveness analysis of the Gen-Probe Amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Micro 41: 948–953.
[14]  Hughes R, Wonderling D, Li B, Higgens B (2012) The cost effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis. Respir Med 106: 300–307.
[15]  Dorman S (2009) Editorial commentary: Coming of age of nucleic acid amplification tests for the diagnosis of tuberculosis. Clin Infect Dis 49: 55–57.
[16]  Dylewski J (2009) Nucleic acid amplification testing for the diagnosis of tuberculosis: Not for all. Clin Infect Dis 49: 1456–1457.
[17]  Marks SM, Cronin W, Venkatappa T, Maltas G, Chon S, et al. (2013) The health system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis 5: 532–532.
[18]  Choi HW, Miele K, Dowdy D, Shah M (2013) Cost-effectiveness of Xpert ? MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 17: 1328–1335.
[19]  Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.
[20]  World Health Organization (2011) Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampin resistance: Xpert MTB/RIF system. A policy statement. Available: Accessed 2013 Oct 30.
[21]  Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005–1015.
[22]  FDA permits marketing of first US test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. FDA News Release July 25th 2013. Available at Accessed on 2013 Aug 26.
[23]  American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2000) Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 161(4 Pt 1): 1376–95.
[24]  Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, et al. (2006) Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet Infect Dis 6: 570–581.
[25]  Dowdy D, O’Brien M, Bishai D (2008) Cost effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1021–1029.
[26]  Rajalahti I, Ruokonen E, Kotom?ki T, Sintonen H, Nieminen MM (2004) Economic evaluation of the use of PCR assay in diagnosing pulmonary TB in a low-incidence area. European Respiratory Journal 23: 446–451.
[27]  Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, et al. (1999) Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353: 444–449.


comments powered by Disqus